Jul 1 |
23andMe and Nightingale partner to pilot blood-based risk detection panel
|
Jun 28 |
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
|
Jun 11 |
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
|
Jun 5 |
23andMe Launches New Genetic Report on Bipolar Disorder
|
Jun 4 |
Why 23andMe Stock Tumbled 10% on Tuesday
|
Jun 4 |
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
|
Jun 3 |
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
|
May 29 |
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
|
May 25 |
23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
May 24 |
Q4 2024 23andMe Holding Co. Earnings Call
|